RaySearch Laboratories AB (publ)
OTC:RSLBF
RaySearch Laboratories AB (publ)
RaySearch Laboratories AB is a medical technology company, which engages in the development of software solutions for improved radiation therapy of cancer. The company is headquartered in Stockholm, Stockholm. The company markets and sells its products mainly in the United States and in Europe through license agreements with medical technology companies and scientific institutions. As of December 31, 2011, 15 of the Company’s products were launched, including the software platform ORBIT (optimization of radiation therapy beams by iterative technique), which is available in its main products, and is a non-clinical system which functions as a research and development environment. Additionally, its solutions include software for optimizing Intensity Modulated Radiation Therapy (IMRT) plans for photons, adaptive technology for IMRT treatments and software for proton treatments. The Company’s commercial partners are Philips, Nucletron and IBA Dosimetry, among others. In April 2014, it established a German subsidiary, RaySearch Germany GmbH.
RaySearch Laboratories AB is a medical technology company, which engages in the development of software solutions for improved radiation therapy of cancer. The company is headquartered in Stockholm, Stockholm. The company markets and sells its products mainly in the United States and in Europe through license agreements with medical technology companies and scientific institutions. As of December 31, 2011, 15 of the Company’s products were launched, including the software platform ORBIT (optimization of radiation therapy beams by iterative technique), which is available in its main products, and is a non-clinical system which functions as a research and development environment. Additionally, its solutions include software for optimizing Intensity Modulated Radiation Therapy (IMRT) plans for photons, adaptive technology for IMRT treatments and software for proton treatments. The Company’s commercial partners are Philips, Nucletron and IBA Dosimetry, among others. In April 2014, it established a German subsidiary, RaySearch Germany GmbH.
Record Sales: Q3 sales reached SEK 293 million, the highest ever for the company, up 19% from last year.
Profitability: Operating profit rose to SEK 62 million with a 21% margin, nearly doubling last year’s margin.
Margin Target Raised: The board increased the 2026 operating margin goal to at least 25%, up from 20%, after achieving the old target two years early.
RayCare Momentum: Major RayCare milestones included first clinical use with a TrueBeam machine and new customer wins; revenue impact expected in 2025.
Operating Costs Controlled: Operating expenses grew just 5%, with management emphasizing ongoing cost discipline to support margin targets.
Strong Pipeline: Despite orders tracking slightly below sales, management expressed confidence in robust demand, especially for RayCare.
